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ABSTRACT Interleukin 3 (IL-3)-dependent survival of
hematopoietic cells is known to rely on the activity of multiple
signaling pathways, including a pathway leading to activation
of phosphoinositide 3-kinase (PI 3-kinase), and protein kinase
Akt is a direct target of PI 3-kinase. We find that Akt kinase
activity is rapidly induced by the cytokine IL-3, suggesting a
role for Akt in PI 3-kinase-dependent signaling in hematopo-
etic cells. Dominant-negative mutants of Akt specifically block
Akt activation by IL-3 and interfere with IL-3-dependent
proliferation. Overexpression of Akt or oncogenic v-akt pro-
tects 32D cells from apoptosis induced by IL-3 withdrawal.
Apoptosis after IL-3 withdrawal is accelerated by expression
of dominant-negative mutants of Akt, indicating that a func-
tional Akt signaling pathway is necessary for cell survival
mediated by the cytokine IL-3. Thus Akt appears to be an
important mediator of anti-apoptotic signaling in this system.
The development of immature bone marrow progenitor cells
is governed by a delicate balance between proliferation and
apoptosis and is controlled by the availability of cytokines in
vivo (for review see ref. 1). Many cytokines not only stimulate
cell growth, but also are necessary for cell survival. Defining
the precise mechanism of cytokine function in cells is therefore
critical for understanding hematopoiesis (for review see ref. 1).
The cytokines interleukin 3 (IL-3) and granulocytey
macrophage colony-stimulating factor (GM-CSF) exert their
survival and proliferative functions through a common signal-
ing subunit, the bc receptor (2). Signal transduction events that
regulate survival by IL-3 and GM-CSF are in part mediated by
cytosolic tyrosine kinases (i.e., Lyn) and subsequent mitogen-
activated protein kinase (MAPK) activation (2–6). A region of
the bc receptor that is sufficient for IL-3 and GM-CSF-
dependent survival induces MAPK activation (2, 3). In the
absence of IL-3, IL-3-dependent progenitor cells quickly un-
dergo apoptosis, but expression of Bcl-2 can support survival
upon IL-3 withdrawal (7, 8).
Another signaling molecule that is activated by IL-3 and
GM-CSF is phosphoinositide 3-kinase (PI 3-kinase) (4, 9, 10).
PI 3-kinase has been implicated in the regulation of survival in
several cell types (for review see ref. 11). PI 3-kinase also is
implicated in IL-3-dependent survival, and a region on the bc
receptor important for IL-3yGM-CSF-dependent survival is
necessary for PI 3-kinase activation (2). Furthermore, an
activated mutant of Ras that stimulates PI 3-kinase activity
(12) can complement mutant bc receptors that are defective in
survival in response to GM-CSF (2). Several downstream
targets of PI 3-kinase recently have been identified, including
p70 ribosomal protein S6 kinase (13), several protein kinase C
isoforms (for review see ref. 14), and the serineythreonine
kinase Akt (15–17).
Akt (also referred to as Raca or PKBa), which also was
identified by its homology to protein kinases A and C, is the
cellular homolog of the v-akt oncogene (18–20). The protein
kinase activity of Akt is directly stimulated by products of PI
3-kinase in vitro (15, 21, 22). In cells, Akt is activated by factors
that stimulate PI 3-kinase activity in cells, such as thrombin,
platelet-derived growth factor, and insulin (for review see ref.
11). Akt also is activated under conditions of cellular stress by
a pathway not involving PI 3-kinase (23). The N-terminal
regulatory domain of Akt contains a Pleckstrin homology
domain (PH) that is important for Akt activation (for review
see ref. 11). Phosphatidylinositol-3,4-bisphosphate directly
binds to the Akt PH domain to stimulate Akt protein kinase
activity (15, 22, 24). Full activation of Akt also requires
phosphorylation on serine and threonine residues (25).
Overexpression experiments using Akt and oncogenic v-akt,
and the use of Akt mutants that interfere with its function in
cells have underscored the importance of Akt in several cell
systems (for review see ref. 11). Akt is able to support the
survival of primary cerebellar granule cells after survival factor
deprivation (26). Activated Akt also prevents apoptosis that is
induced after exposure of fibroblast and epithelial cells to
ultraviolet radiation (27), after conditional expression of c-myc
in fibroblast cell lines (28, 29), and after detachment of MDCK
epithelial cells from their extracellular matrix (anoikis) (30).
Little knowledge, however, exists about the function of Akt in
hematopoietic cells, even though c-akt originally was identified
as a transduced oncogene in a T cell lymphoma-inducing
retrovirus in AKR mice (31). One study recently has examined
the ability of activated forms of Akt to prevent cell death
induced by withdrawal of IL-2 from BAFy3 cells expressing the
IL-2 receptor (32).
Here we show that Akt activity is induced rapidly by the
cytokine IL-3 and that the activation of Akt by IL-3 is
dependent upon the activity of PI 3-kinase. Our results suggest
a central role for Akt in PI-3 kinase signaling in IL-3-
dependent cells. Akt and v-akt expression significantly pre-
vented apoptosis of IL-3-dependent cells in the absence of
IL-3, suggesting an important role for the Akt kinase in cell
survival. In addition, the expression of dominant-negative
mutants of Akt interfered with Akt activation by IL-3 and
promoted apoptosis. We failed to observe the induction of
Bcl-2 expression in cells overexpressing Akt. The role for Akt
in IL-3-dependent cell survival could explain the transforming
potential of v-akt in hematopoietic cells.
MATERIALS AND METHODS
Cell Lines, Expression Constructs, and Transfections. 32D
cells were maintained in RPMI medium 1640 with 10% fetal
calf serum (FCS) and 10% WEHI-3 conditioned medium (33).
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Human Bcl-2 in pSV is described in ref. 7. The retroviral vector
pLXSN and v-akt in pLXSN were previously described (34).
Hemagglutinin (HA) epitope-tagged expression constructs of
HA-Akt, HA-Akt(K179M), and HA-Akt(PH) were generated
by transferring pre-existing constructs from pJ3V (15, 35) into
the retroviral vector pBabe (36). Inserts of HA-Akt, HA-
Akt(K179M), and HA-Akt(PH) were excised by digestion with
HindIII and BamHI, and blunted and inserted into the SnaBI
site of pBabe by blunt-end ligation. All constructs were verified
by sequence analysis.
Cells expressing the various Akt constructs were generated
by transfecting 32D cells. Mass cultures of 32D cells were
selected in 2 mgyml puromycin (Sigma). To generate v-akt
expressing cells, 32D cells were either electroporated with
v-akt in pLXSN or infected with retroviruses that were gen-
erated by transient expression of v-akt in pLXSN in the
retroviral packaging line BOSC-23 (37). Mass cultures of v-akt
expressing cells were selected in 400 mgyml G418 (GIBCOy
BRL).
Cell Proliferation and Survival Assays. Cell proliferation
was monitored by [3H]thymidine uptake as previously de-
scribed (33). Cell survival was determined by counting viable
cells using the trypan blue exclusion method (38). Briefly, 32D
cells carrying control vectors and cells expressing v-akt, HA-
Akt, HA-Akt(K179M), HA-Akt(PH), andyor Bcl-2 were
washed with RPMI containing 10% FCS and antibiotics to
deplete of IL-3. For [3H]thymidine uptake experiments, cul-
tures of 1 3 105 cells were grown in 24-well plates at different
concentrations (0.01% to 10%) of WEHI-3 conditioned me-
dium. After 48 hr, 1 mCi of [3H]thymidine was added to each
well for 6 hr. Incorporated radioactivity was estimated by
liquid scintillation counting. For survival assays, IL-3-depleted
cells were seeded at a density of 2 3 105 per ml in RPMI
containing 10% FCS. To determine the effect of DNA damage
reagents on cell survival, etoposide (Sigma) was added at
different concentrations to RPMI medium containing 10%
FCS and WEHI-3 conditioned medium. Subsequently, the
ratio of viable to dead cells was determined by trypan blue
exclusion.
Immunoblotting, Immunoprecipitation, and Immunocom-
plex Kinase Assays. Cultures of 32D cells transfected with
control vectors and various Akt constructs were depleted of
IL-3 by brief washing in RPMI containing 10% FCS. Cells were
starved for 30 min in the same media, and then transferred to
RPMI without serum. Wortmannin (Sigma) was added at 100
nM where indicated. Cells (5 3 106) were stimulated 30 min
later with 1–2 ngyml of recombinant IL-3 (R & D Systems or
PeproTech, Boston) in RPMI 1640 medium and lysed by the
addition of an equal volume of 23 Nonidet P-40 lysis buffer (40
mM TriszHCl, pH 8.0y274 mM NaCly20% glyceroly2% Non-
idet P-40y2 mM phenylmethylsufonyl f luoridey4 mg/ml apro-
tininy4 mg/ml leupeptin). Endogenous Akt was immunopre-
cipitated from cell lysates using Akt-CT antibody (15). HA-
epitope tagged Akt constructs were immunoprecipitated using
monoclonal anti-HA antibody (Boehringer). Akt activity was
determined by in vitro kinase assays using histone H2B as a
substrate (15). Immunocomplex kinase assays were displayed
by 12.5% crosslinked SDSyPAGE and blotted onto nitrocel-
lulose. After exposure to PhosphoImager (Bio-Rad) and x-ray
film, blots were probed with anti-Akt-CT to ensure equal
protein loading.
To visualize the Akt N terminus in cells transfected with
HA-Akt[PH], immunoblots were performed using the Akt-NT
antibody (21). To examine the phosphorylation state of
MAPK, whole-cell lysates were resolved by crosslinked 7.5%
SDSyPAGE and transferred onto nitrocellulose membranes.
Immunoblots were performed using anti-ERK (Santa Cruz
Biotechnology).
RESULTS
To determine whether Akt is involved in the IL-3-dependent
survival pathway, we tested whether Akt is activated by IL-3 in
the myeloid progenitor cell line 32D. Addition of IL-3 to 32D
cells increased the activity of immunoprecipitated Akt toward
histone H2B .3-fold within 1 min (Fig. 1A). Akt activation by
IL-3 was PI 3-kinase-dependent based on inhibition by the PI
3-kinase inhibitor wortmannin (Fig. 1 A). To further investi-
gate the activation of Akt, we generated stable 32D cell lines
expressing HA-tagged wild-type Akt (HA-Akt) and kinase-
inactive Akt with a point mutation in the ATP binding site
[HA-Akt(K179M)] (15). Both proteins were expressed (Fig.
1B). As judged by histone H2B kinase activity in anti-HA
immunoprecipitates, the protein kinase activity of HA-Akt,
but not HA-Akt(K179M), was stimulated about 3–4 fold by
IL-3 in 32D cells (Fig. 1B). Thus, the observed histone H2B
kinase activity after IL-3 stimulation can be demonstrated with
HA-tagged proteins and requires the active site, implying that
direct activation of Akt is responsible for the activity in
anti-Akt immunoprecipitates rather than a coprecipitating
kinase being responsible.
Kinase-inactive Akt can block okadaic acid-induced inhibi-
tion of glycogen synthase kinase-3 (39). Furthermore, recent
findings demonstrated that kinase-inactive Akt and a mutant
of Akt that lacks the kinase domain block the survival of
cerebellar granule cells, indicating the dominant-negative ef-
fect of these mutants in the Akt-dependent survival pathway
(26). To test whether overexpression of the Akt regulatory
domain also could interfere with IL-3-dependent activation of
endogenous Akt, we measured the activity of endogenous Akt
in cells expressing the N terminus of Akt, which includes the
PH domain but lacks the kinase domain [HA-Akt(PH)]. After
FIG. 1. Akt is activated by IL-3 depending upon the activity of PI-3
kinase. (A) 32D cells were starved of IL-3 as described above and
stimulated with 1 ngyml IL-3 (Materials and Methods). Subsequently,
the kinase activity of Akt was determined by histone H2B phosphor-
ylation in immunoprecipitates using anti-Akt-CT. Akt kinase activity
also was determined in immunoprecipitates from cells that were
pretreated with 100 nM wortmannin before IL-3 stimulation. Subse-
quently, the immunoprecipitates were probed with anti-Akt-CT to
ensure equal protein loading. (B) 32D cells expressing HA-Akt or
HA-Akt(K179M) were starved of IL-3 and stimulated for various
times with 2 ngyml IL-3. HA-Akt and HA-Akt(K179M) proteins were
immunoprecipitated with monoclonal anti-HA before and after stim-
ulation, and their kinase activity was monitored by in vitro kinase. The
lower panel shows an anti-Akt-CT immunoblot of the immunopre-
cipitates.
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IL-3 stimulation, control cells and cells expressing HA-
Akt(PH) were lysed and endogenous Akt was immunoprecipi-
tated (15). The expression of HA-Akt(PH) reduced the activ-
ity of endogenous Akt in starved cells and cells that were
stimulated with IL-3 to less than 20% of the activity observed
in the control cells (Fig. 2). Even though the inhibition of Akt
activity was not complete, our results indicated that HA-
Akt(PH) acts as a dominant-negative mutant for the Akt
survival pathway by reducing its activity and blocking its ability
to be activated by IL-3. To test if the signaling block by
HA-Akt(PH) was specific for Akt, we also tested mobility shift
(Fig. 2) and activity (data not shown) of MAPK that is
activated by IL-3 in 32D cells. Consistent with previous studies,
addition of IL-3 to starved 32D cells led to a mobility shift of
MAPK within 5 min, indicative of the activation of these
kinases (Fig. 2). MAPK activation by IL-3 was not affected by
expression of HA-Akt(PH), indicating that the inhibitory
effect of HA-Akt(PH) on Akt signaling is specific for the Akt
pathway. This result also suggests that Akt is not required for
IL-3-dependent activation of MAPK.
The role of Akt in IL-3-dependent biological responses was
studied in 32D cells expressing different forms of Akt or
oncogenic v-akt. A consistent promotion of IL-3-dependent
DNA synthesis coincident with expression of v-akt or HA-Akt
was observed at low, but not high, doses of IL-3 (Fig. 3 A and
B). Furthermore, a dominant-negative mutant of Akt inhibited
DNA synthesis at both high and low IL-3 (Fig. 3 A and B).
These results imply that Akt may be involved in proliferative
responses although it is difficult to separate proliferation and
survival.
Previous studies have shown that withdrawal of IL-3 induces
apoptosis in IL-3-dependent 32D cells (7). DNA laddering that
is characteristic of apoptosis occurred after switching 32D cells
to IL-3-free growth medium (data not shown). Treatment of
cells with the PI 3-kinase inhibitor LY294002 in the presence
of IL-3 induced apoptosis in IL-3-dependent cells (10), sug-
gesting that PI 3-kinase may play an important role in IL-3-
dependent cell survival. To test whether Akt can mediate
survival, we investigated cells expressing various Akt con-
structs. Mass cultures of cells expressing either vector alone or
v-akt were starved of IL-3, and cell survival was monitored
over 5 days using the trypan blue dye exclusion assay (38). For
the cells expressing the vector control, within 16 hr substantial
apoptosis occurred (approximately 50% dead cells) and by 72
hr virtually all cells were dead (Fig. 4A). Expression of human
Bcl-2 partially prevented apoptosis of 32D cells, in agreement
with previous studies (7). Expression of oncogenic v-akt, a
constitutively activated Akt kinase (15), also partially blocked
cell death, though the effect was not as potent as that of Bcl-2.
At 24 hr after IL-3 withdrawal, .50% of the v-akt-expressing
cells were viable compared with 35% of control cells (Fig. 4A).
At 72 hr, 99% of control cells had died; in contrast, approx-
imately 20% of v-akt-expressing cells still remained viable after
5 days, suggesting a significant protective function of v-akt
(data not shown). However, this protocol may underestimate
the protection by v-akt, because pools of G418-resistant cells
were used and the protein expression level of v-akt was almost
10-fold lower than that of endogenous Akt (data not shown).
To further examine the ability of Akt to increase cell
survival, pools of cells were transfected with pBabe vector
alone or with constructs expressing HA-Akt, HA-
Akt(K179M), or HA-Akt(PH). Overexpression of HA-Akt
significantly attenuated apoptosis that was triggered by deple-
tion of IL-3. At 24 hr of IL-3 starvation, more than 60% of
HA-Akt-expressing cells were still alive, but less than 20% of
the control cells survived (Fig. 4B). The level of protection by
Akt at this time was nearly that reached by Bcl-2 expression
(Fig. 4B). Dominant-negative mutants of Akt accelerated IL-3
depletion-induced cell death: less than 8% of the cells express-
ing HA-Akt(PH) and only 1% of the cells expressing HA-
Akt(K179M) survived after 24 hr. Therefore, Akt both can
mediate cell survival in the absence of IL-3 and is needed for
IL-3-mediated survival. The survival function of Akt was
transient when compared with that of constitutively activated
v-akt: by 48 hr of IL-3 depletion, 95% of cells expressing
HA-Akt also had died (data not shown).
Because both Akt and Bcl-2 can protect 32D cells from
apoptosis, we tested whether the Akt- and Bcl-2-mediated
survival pathways overlapped. First, we studied the effects of
Akt expression on Bcl-2-dependent cell survival. 32D cells
expressing human Bcl-2 and murine Akt were generated by
cotransfecting constructs directing the expression of Bcl-2 and
HA-Akt or its mutants. Bcl-2 was expressed at similar amount
in all cells (data not shown). Expression of Akt and its mutants
and the activation of Akt and HA-Akt by IL-3 were not
affected in cells that were expressing Bcl-2 (data not shown).
Expression of HA-Akt and Bcl-2, however, impaired survival
of 32D cells and reduced it to the level of protection that was
observed after expression of HA-Akt alone (Fig. 4B). Domi-
nant-negative HA-Akt(K179M) had no significant effect on
Bcl-2-mediated survival (Fig. 4B).
Akt also may act by reducing apoptosis induced through
DNA repair. To test if v-akt was able to protect 32D cells from
apoptosis that is induced by DNA damaging reagents, we
exposed control cells and cells expressing Bcl-2 or v-akt for 16
hr to the DNA damaging reagent etoposide in growth medium.
Etoposide has been shown to induce apoptosis in other
IL-3-dependent cell lines, including BAFy3 cells, by inhibiting
topoisomerase II (40). Cell death, as measured by the dye
exclusion method, was induced by increasing concentrations of
etoposide, and the expression of v-akt efficiently blocked
etoposide-induced apoptosis (Fig. 5). Bcl-2 was somewhat
more efficient at blocking etoposide-induced apoptosis (Fig.
5).
DISCUSSION
Akt acts in multiple signaling systems as a downstream target
of PI 3-kinase: this includes activation of Akt in signaling
pathways that originate from activated receptor tyrosine ki-
nases (15, 16, 41) and G protein-coupled receptor systems like
the thrombin receptor (21). Here, we report that Akt is
FIG. 2. Activation of endogenous Akt by IL-3 is inhibited by
expression of the Akt N terminus. The kinase activity of endogenous
Akt was determined by histone H2B phosphorylation in anti-Akt-CT
immunoprecipitates from 32D cells stimulated with IL-3 (1 ngyml).
Akt activity was measured in immunoprecipitates from cells trans-
fected with pBabe vector alone as well as from cells transfected with
HA-Akt(PH) in pBabe. Whole-cell lysates were blotted with anti-
Akt-CT and anti-Akt-NT to determine expression of Akt and the Akt
N terminus, respectively. In parallel, MAPK mobility shifts were
determined by anti-Erk immunoblotting of whole-cell lysates after
electrophoresis in 7.5% SDSyPAGE.
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activated as a consequence of cell stimulation by a cytokine in
agreement with a recent study (32). IL-3-dependent activation
of Akt probably is mediated by activation of PI 3-kinase
because an inhibitor of PI 3-kinase, wortmannin, blocks Akt
activation in response to IL-3. Previous studies have shown that
the activity of Akt is regulated directly by products of PI
3-kinase that bind to the Akt PH domain (21, 22, 24).
Phosphorylation of Akt is important for its activation and the
major phosphorylation sites, threonine 308 and serine 473,
have been identified (25). Hence, IL-3-dependent activation of
Akt is likely to be governed by lipid binding and phosphory-
lation events. Furthermore, the Akt signaling pathway in 32D
cells is probably distinct from pathways leading to MAPK
activation, given that dominant-negative mutants of Akt in-
hibited endogenous Akt activation without blocking MAPK
activation.
Consistent with PI-3 kinase being a survival factor in several
different tissue culture systems and Akt being a direct target
of PI-3 kinase (for review see ref. 11), we demonstrate here
that Akt also promotes survival after IL-3 withdrawal. Expres-
sion of Akt and its oncogenic form, v-akt, prevented apoptosis
that is initiated by IL-3 withdrawal (Fig. 4). Although Akt and
v-akt were equally potent in protecting cells from apoptosis
immediately after IL-3 starvation, only v-akt showed a long-
term anti-apoptotic effect (Fig. 4A). This difference is con-
sistent with differences in the activity of the two molecules:
cytoplasmic Akt is transiently activated upon stimulation of PI
3-kinase and phosphorylation, whereas v-akt is constitutively
activated by being localized to the plasma membrane (15). Our
studies using dominant-negative forms of Akt underscored the
importance of Akt for cell survival. Expression of dominant-
negative HA-Akt(PH) and HA-Akt(K179M) accelerated apo-
ptosis in 32D cells (Fig. 4). In the presence of IL-3, dominant-
negative Akt also partially inhibited IL-3-dependent prolifer-
ation (Fig. 3). Recently, by using our set of dominant-negative
mutants, Akt was shown to be important for IGF-1-dependent
survival of primary cerebellar neurons (26). These data are in
good agreement with our present findings. Taken together
with other recent work (27–29, 32), they suggest a general
anti-apoptotic function for Akt. Thus, among the various
targets of PI-3 kinase, Akt is probably the major mediator of
the survival function of PI-3 kinase.
Our results suggest that Akt is using a mechanism for cell
survival that seems not to involve Bcl-2. Akt and Bcl-2 failed
to synergize in protection of cells from apoptosis. Further-
more, the overexpression of HA-Akt reduced the level of
Bcl-2-mediated protection to the level that was observed after
expressing HA-Akt alone. More importantly, expression of
FIG. 3. Proliferation of cells expressing Akt constructs. The proliferation of 32D cells expressing various Akt constructs was measured at various
levels of IL-3 using the [3H]thymidine uptake assay (see Materials and Methods). The error bars indicate the standard error of four experiments.
(Left) [3H]thymidine uptake was determined in cells transfected with vector alone or v-akt in pLXSN. (Right) [3H]thymidine uptake also was
measured in cells transfected with pBabe alone and HA-Akt or HA-Akt(K179M) in pBabe.
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dominant-negative Akt with Bcl-2 did not compromise the
Bcl-2-dependent survival. Even though these results do not
exclude Bcl-2 or another family member being downstream of
Akt, they suggest that Akt does not play a role in Bcl-2-
dependent survival. In addition, we failed to observe a change
in the migration pattern of Bcl-2 in HA-Akt overexpressing
cells that is indicative of Bcl-2 phosphorylation (data not
shown), which is important for its anti-apoptotic function (42).
A recent paper has implicated Akt in prevention of apoptosis
after withdrawal of IL-2 by a mechanism that is claimed to lead
to an increase in the expression levels of c-myc and Bcl-2 (32).
Bad, a member of the Bcl-2 family that is rapidly phosphor-
ylated upon IL-3 stimulation (43), can attenuate Bcl-2 activity
by heterodimerization with Bcl-2 (for review see refs. 44 and
45). It will be interesting to study whether IL-3-dependent Bad
phosphorylation is mediated by Akt. To date, only glycogen
synthase kinase-3 has been identified as a direct downstream
target of Akt (39), and it remains to be determined if the role
of glycogen synthase kinase-3 in the regulation of cell prolif-
eration by phosphorylating the adenomatous polyposis coli
gene product APC (46) is important for Akt-mediated sur-
vival.
Our data indicate that Akt, presumably acting as a down-
stream effector of PI 3-kinase, has an important role in the
survival of IL-3-dependent cells. Thus, Akt differs from other
signaling molecules such as MAPK because of its rapid
activation (this report) and from p70 ribosomal protein S6
kinase because of its role in cell survival (26, 29). Expression
of oncogenic v-akt also prevented apoptosis induced by the
DNA damaging agent etoposide (Fig. 5). This may be relevant
to the therapy of those human cancer forms that are charac-
terized by enhanced expression of the human protooncogene
AKT2 that is closely related to Akt and v-akt (90% similarity
on the protein level) (47, 48).
The discovery of phosphatases that regulate the ratio of
D3-phosphorylated phosphoinositides (49–54) adds further
complexity to the understanding of signaling cascades down-
stream of PI 3-kinases. Recent studies have demonstrated that
the phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase
SH2-containing inositol phosphatase (SHIP) associates with
the activated IL-3 receptor (55, 56). Interestingly, SHIP ap-
pears to counteract the protective function of PI 3-kinase (2)
and Akt (this report) in IL-3-dependent survival by inducing
apoptosis in an IL-3-dependent cell system (57). This could be
due to the ability of SHIP to recruit negative regulatory
molecules to the IL-3-dependent signaling complex.
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